MARKET EYE-Credit Suisse upgrades Dr Reddy's on US outlook

Thu Dec 13, 2012 9:15am IST

Related Topics

Stocks

   

* Credit Suisse upgrades Dr. Reddy's Laboratories to
'outperform' from 'neutral' and raises its target price to 2,150
rupees from 1,900 rupees, citing expectations for a strong pick
up in U.S. sales in the coming quarters.
* Credit Suisse also notes the market share for Dr. Reddy's
Metoprolol drug, used for hypertension, is increasing.
* Dr. Reddy's also expects upcoming approval of two limited
competition products in the United States, Credit Suisse says
after meeting with the drug maker's management.
* Dr. Reddy's also expects fiscal 2015 growth in the United
States to be stronger than fiscal 2014 due to some "significant"
launches.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Importing Iron Ore

REUTERS SHOWCASE

Diesel Deregulation

Diesel Deregulation

India to decide on diesel deregulation after state polls - govt source.  Full Article 

Drug Approval

Drug Approval

Epirus, Ranbaxy win India approval for arthritis drug copy.  Full Article 

Rajan Speaks

Rajan Speaks

RBI chief Rajan says limiting reliance on foreign debt.  Full Article 

Debt & Equity Deal

Debt & Equity Deal

KKR to lend $175 million to GMR Infrastructure - source.  Full Article 

Preparing for IPO

Preparing for IPO

Alibaba boosts IPO as demand strengthens.  Full Article 

India-Vietnam Ties

India-Vietnam Ties

India tightens Vietnam defence, oil ties ahead of China Xi's visit.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage